Fluorouracil and folinic acid bolus schedule (nordic regimen) combined with irinotecan as a first-line chemotherapy in metastatic colorectal cancer

Year 2010, Volume: 15 Issue: 1, 7 - 14, 15.01.2013

Yüksel Küçükzeybek Bülent Karabulut Halit Yetiş Rüçhan Uslu Ulus A. Sanli Adem Uslu Cengiz Demir Erdem Göker

Abstract

Abstract. The recent incorporation of irinotecan (CPT-11) for the management of advanced colorectal cancer has generated further improvement in survival. The goal of this retrospective analysis was to evaluate the efficacy and toxicity of irinotecan plus bolus FU/FA (Nordic regimen) as first-line therapy in patients with advanced colorectal cancer. A total of 43 patients with metastatic colorectal cancer treated with irinotecan plus bolus FU/FA (Nordic regimen) as first-line chemotherapy were reviewed. Patients with metastatic adenocarcinoma of the colon or rectum and who had measurable disease and WHO performance status of 2 or less were treated with irinotecan 210 mg/m² as a 30-90 min intravenous infusion on day 1, followed by 5-FU 500 mg/m² and FA 60 mg/m² bolus on days 1 and 2, every 2 weeks, until disease progression or unacceptable toxicity. Patients were evaluated for response rates, survival and toxicity. Median patient age was 56 (29-76) years. Response rates were 72% as a carcino embryogenic antigen (CEA) level and 45% as a clinic evaluation. Disease control rates were 76% as a CEA level and 80% as a clinic evaluation. Median duration of response was 5,8 (2-9) months as a clinic evaluation and median duration of response was 6,6 (2-11) months as a CEA level. Median progression free interval was 9 (2-13) months and median overall survival was 16 (3-18) months. Grade 3-4 neutropenia occurred in 30% of the patients. Non-haematological toxicities were mild. There was no treatment-related death. Irinotecan - Nordic regimen is considered as a reasonable option for first-line treatment of patients with metastatic colorectal cancer

Key words: First-line chemotherapy,metastatic colorectal cancer, nordic regimen, irinotecan

Keywords

-

References

• Greenlee RT, Hill-Harmon MB, Murray T et al. Cancer statistics, 2001. CA Cancer J Clin 2001; 51:15-36.
• Parkin Dm, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49: 33-64.
• Midgley R, Kerr D. Colorectal cancer. Lancet 1999; 353:391-399.
• Steele G Jr, Osteen RT. Surgical treatment of colon cancer. In steele G Jr, Osteen RT (eds, colorectal cancer: Current Concepts in Diagnosis and Treatment. New York: Marcel Dekker 1986, pp 127-162.
• Zaheer S, Pemberton JH, Farouk R et al. Surgical treatment of adenocarcinoma of the rectum. Ann Surg 1998; 227: 800-811.
• Midgley R, Kerr D. Conventional cytotoxic and novel therapeutic concepts in colorectal cancer. Expert Opin Investig Drugs 2001; 10: 1011-1019.
• Skibber JM, Minsty BD, Hoff PM. Cancer of the colon. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer, Principles and Practise of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams / Wilkins 2001, pp 1255.
• Ragnhammar P, Hafstrom L, Nygren P et al. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001; 40: 282-308.
• Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301-308.
• Hansen RM. 5- fluorouracil by protracted venous infusion: a review of recent clinical studies. Cancer Invest 1991; 9: 637-642.
• Rougier P, Paillot B, Laplanche A et al. 5fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of randomized trail in metastatic colorectal cancer. Eur J Cancer 1997; 33: 1789-1793.
• Leichman CG, Fleming TR, Muggia FM et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995; 13: 1303-1311.
• Lokich JJ, Ahlgren JD, Gullo JJ et al. A prospective randomized comparison of continuous infusion fluorouracil with a convantional bolus Schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989; 7: 425-432.
• Saltz LB, Cox JV, Blanke C et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905914.
• Cunningham D, Pyrhonen S, James RD et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorecatal cancer. Lancet 1998; 352: 1413-1418.
• Tsavaris N, Kosmas C, Vadiaka M et al. Raltitrexet (tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colrectal cancer: a pilot study. Invest New Drugs 2002; 20:133-136.
• Kempin S, Gutierrez J, Wilson Eet al. Raltitrexet (Tomudex): an alternative choise in patients intolerant to 5-fluorouracil. Cancer Invest 2002; 20: 992-995.
• Park SH, Bang SM, Cho EK et al. First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. Oncology 2004; 66: 353-357.
• Hoff PM, Pazdur R, Lassere Y et al. Phase II study of capecitabine in patients with fluorouracil resistant metastatic colorectal carcinoma. J Clin Oncol 2004; 22: 2078-2083.
• de Gramont A, Figer A, Seymour M et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 29382947.
• O’Neil BH,Goldberg RM. Novel chemotherapeutic and targeted agents in metastatic colorectal cancer. The times has arrived. Expert Opin Investing Drugs 2003; 12:1939-1949.
• Andre T, Boni C, Mounedji-Boudiaf L. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
• Cunningham D, Pyrhonen S, James RD et al: Randozed trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorecatal cancer. Lancet 1998; 352:1413-1418.
• Rougier P, Van Cutsem E, Bajetta E et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407-12.
• Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000; 355: 1041-47.
• Saltz LB, Douillard JY, Pirotta N, et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 2001; 6: 81-91.
• Glimelius B, Ristamaki R, Kjaer M, et al. Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Annals of Oncology 2002; 13: 1868-73.